TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > PharmaLex Internal Audit Programme Management Services

PharmaLex Internal Audit Programme Management Services

Maintaining regulatory compliance across the product lifecycle is critical to ensuring the continuity of your operations. Whether your organisation is virtual or fully in-house, internal auditing is a mandatory component of maintaining regulatory compliance.

Audits are an essential part of the Quality Management System (QMS) and are mandatory as part of management responsibilities indicated in the following regulations and guidelines.

  • 21 CFR 820.20, Management Responsibility: here
  • European Commission, EudraLex, Volume 4, Chapter 1, Pharmaceutical Quality System: here
  • ICH, Q10 Pharmaceutical Quality System (ICH, April 2009): here

Audits support an organisation in accomplishing its objectives by bringing a systematic approach to evaluating and improving the effectiveness of risk management, process control and governance systems. Effective audit programmes should not only help ensure compliance and drive continuous improvement, they should deliver substantial benefits to companies in their ability to be current in the continuously changing regulatory environment and industry best practices. Audits provide confirmation that systems are fit for use and are working well. To reap the full benefit of the internal audit system, a well-planned, resourced, consistent, fully engaged and documented programme is required.

It is important to remember that if an internal audit programme is developed and implemented appropriately, it can provide key information to identify concerns or prevent issues before they lead to serious compliance issues.  Internal awareness of weak or high-risk areas provides an organisation with time to make decisions on how to address the issues before a regulatory inspector observation is obtained. Even in the midst of a regulatory inspection, the self-identification of an issue, and having a plan or action in place to address that issue will instil confidence in your regulatory inspector that you have systems in place to continuously improve your operations.

Below are the top ten tips that PharmaLex recommend for the successful roll out of an audit management programme:

  • Consider the structure of the audit program carefully. Take a risk-based approach to the frequency of the audits. However, include a minimum frequency to ensure no area is overlooked. Consider if you wish to have audits on systems, functional areas or a combination of both.
  • Train your audit team well. Have you an auditor certification program? What training or mentoring must they have completed to be an internal auditor? Have you lead auditors available to mentor newer auditors? Complete refresher training with internal auditors. Consistency in approach for each audit is key to good engagement and best follow-up results. Keep them up to date with regulatory changes, observation trends, and risk areas.
  • Prepare an audit schedule periodically. The schedule should include the auditor and auditee area. Remember auditors should be independent of the area they are auditing. Inform the auditors and auditees of the schedule as soon as it is issued.
  • Auditors should plan the audit with the functional area well in advance. This gives the functional area time to prepare for the audit and an audit agenda should be prepared. In advance of the audit, identify any higher risk areas with the relevant personnel. Take a risk-based approach and plan to apportion audit time to higher risk areas.
  • At the start of the audit, have an opening meeting with all of the functional area, if possible. An internal audit should be a collaboration between the function being audited and the auditor. It should be an open, honest, collaborative, learning forum where functional areas have the opportunity to discuss concerns and actions openly.
  • During the audit, auditors should be direct and avoid asking questions designed to catch people out or undermine auditees. The auditors should take this opportunity to explain to the auditees why they are asking particular questions and provide the regulatory reference for the inquiry. Another important auditor behaviour is to listen carefully to the answers to the questions. The auditor should adopt an approachable manner and avoid confrontation.
  • Individuals who are responsible for performing the day-to-day activities often have the best insight into what works and what requires improvement. Excluding these individuals from participating in the audit process might result in overlooking issues that could come up during a regulatory inspection.
  • Audits should remain objective and avoid being overly judgemental. The process should also avoid ‘audits for audit’s sake’ and just ticking the box to progress to the next audit. Positive and forward focussing actions and outcomes should result from the audit programme.
  • Have a close out meeting. There should be no surprises here as the collaborative style of the audit means that any issues will have been discussed during the audit.
  • Prepare an audit report and capture the Corrective and Preventative Actions on a tracker with a due date and ensure closer of the actions. These, as with all CAPA actions, should have management oversight.

Effective audit programmes require appropriate time and resources which PharmaLex can provide. PharmaLex has built up a wealth of expertise over the years and have a proven record in the ability to deliver audits and audit programmes, internally and externally, in line with their company motto: “Confidence beyond Compliance”. PharmaLex has a team of GxP consultants that come from a wide variety of backgrounds who can perform audits in compliance with global GxP regulations. This allows for maximum flexibility to provide technically suitable and centrally located auditors for each audit when needed.  Audits are conducted using a “hat-on/hat-off” approach in which the auditor provides feedback to the auditee during the audit. This real-time mentoring improves auditee performance, preparedness and confidence for upcoming GxP inspections. PharmaLex auditors provide piece of mind auditing; they are responsible for all audit preparation, onsite auditing, and audit reporting.  Following the audit, PharmaLex can support post-audit activities such as CAPAs and remediation activities to closure.

If you would like advice or support in relation to the development, improvement or execution of an audit management programme why not get in touch to find out more on the range of services that we offer and how we can help you by connecting with us on +353 1 846 4742 or email us at contactirl@pharmalex.com.

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Thanks so much for your support over the past 30 days. Your commitment and timely communication have made working with you all a pleasant experience.

    US Biotech
    Senior QA Associate
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for